Steve Levine, MD: Psychedelics and Psychiatry


There are a number of ongoing clinical trials testing psychedelics as a treatment for psychiatric disorders.

While psychedelics show promise in treating a number of psychiatric disorders, matching the right treatment for the right disorder for the individual patient is still being examined.

Currently, there are a number of clinical trials testing this class of drug for disorders like major depressive disorder (MDD), mood disorders, post-traumatic stress disorder (PTSD), and generalized anxiety disorder (GAD).

And there are several different psychedelics being tested, including psilocybin, LSD, MDMA, DMT, 5-MeO-DMT, and ibogaine.

Psychedelics are grouped in 2 different ways—classical psychedelics, including compounds that act at a certain receptor in the 5-HT2A receptor in the brain and other classes of psychedelics which do not act at that receptor, but causes a similar experience.

In an interview with HCPLive®, Steve Levine, MD, Co-Founder and Chairman of Heading Health, explained how psychedelics can transform psychiatric care.

Levine said this class of compound has been examined for psychiatric disorders for several decades, but it is still primitive in the correct usage.

In addition, psychedelics are unlikely to be used as a stand-alone treatment or a first-line treatment.

Levine explained how clinical trials are ongoing and will dictate if or when psychedelics like psilocybin will be used in the future for which indications and patients.

Related Videos
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
© 2024 MJH Life Sciences

All rights reserved.